A trial looking at buparlisib for HER2 positive breast cancer that has spread to the brain
| ISRCTN | ISRCTN38635575 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN38635575 |
| EudraCT/CTIS number | 2015-003103-27 |
| Secondary identifying numbers | 20750 |
- Submission date
- 30/01/2017
- Registration date
- 31/01/2017
- Last edited
- 13/07/2018
- Recruitment status
- Stopped
- Overall study status
- Stopped
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Lay summary under review by external organisation
Contact information
Miss Helen Scott
Public
Public
Cancer Research UK Liverpool Cancer Trials Unit
Block C, Waterhouse Building
1-3 Brownlow Street
Liverpool
L69 3GL
United Kingdom
| Phone | +44 (0)151 794 8209 |
|---|---|
| hscott@liv.ac.uk |
Study information
| Study design | Non-randomised; Interventional; Design type: Treatment, Drug |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised study |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | A proof of concept phase II study of Buparlisib in HER2 positive breast cancer with brain metastasis following HER2 directed monoclonal antibody therapy |
| Study acronym | BLUEBELL |
| Study objectives | The aim of this study is to evaluate the effects of two-weeks preoperative therapy with buparlisib in women with previously confirmed HER2-positive breast cancer with newly diagnosed brain metastasis following HER2-directed antibody therapy and who are considered a candidate for brain resection surgery. |
| Ethics approval(s) | North West - Haydock Research Ethics Committee, 22/02/2016, ref: 16/NW/0066 |
| Health condition(s) or problem(s) studied | Specialty: Cancer, Primary sub-specialty: Breast Cancer |
| Intervention | All patients enrolled on the trial will receive the study drug buparlisib. Patients will take 100mg of buparlisib once daily until the day before scheduled neurosurgery. Neurosurgery will be scheduled 15-18 days from commencing treatment, and so patients will take the study treatment for 14-17 days. After patients have completed 14-17 days treatment, they will receive scheduled surgery one day later (day 15-17). After this, patients will return 14 days post-surgery and the following procedures will be carried out at this visit: 1. Physical Examination 2. Vital signs 3. ECOG performance status 4. Haematology and clinical biochemistry 5. HbA1c 6. Mood questionnaires 7. Review/recording of concomitant medications 8. Assessment & recording of adverse events Following this, patients will return again on Day 42, and the following procedures will be carried out: 1. Mood questionnaires 2. Review/recording of concomitant medications 3. Assessment & recording of adverse events Adverse events will be recorded until 30 days post treatment. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase II |
| Drug / device / biological / vaccine name(s) | Buparlisib |
| Primary outcome measure | “Response” to buparlisib, defined as a 25% or greater reduction in FLT uptake after 14 days of treatment, measured using FLT-PET scans at baseline and 14 days. |
| Secondary outcome measures | 1. Difference between Intratumoral and serum buparlisib concentrations, measured using tumour and serum samples taken at the time of surgery 2. Difference between cerebrospinal fluid and serum buparlisib concentrations, measured using cerebrospinal fluid/serum samples taken at the time of surgery 3. Ki67 proliferation index, within resected brain metastasis following buparlisib, measured using tumour samples taken at the time of surgery 4. Presence or absence of PIK3CA mutations in cell free DNA as measured by the changes in FLT uptake by PET scanning at baseline and 14 days 5. Presence or absence of PIK3CA mutations in cell free DNA as measured by the changes in FLT uptake by PET scanning at baseline and 14 days 6. Size of brain metastasis as assessed by MRI with gadolinium contrast enhancement at baseline and 14 days 7. Occurrence of SAEs and toxicities according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v 4.03), measured using SAEs & AEs recorded from registration to 30 days post treatment, and mood questionnaires at baseline, 7, 14, 28 and 42 days |
| Overall study start date | 01/06/2015 |
| Completion date | 10/10/2019 |
| Reason abandoned (if study stopped) | Objectives no longer viable |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | Planned Sample Size: 24; UK Sample Size: 24 |
| Key inclusion criteria | 1. Female 16 years or above 2. Histologically confirmed HER2-positive breast cancer (immunohistochemistry 3+ or fluorescence in situ hybridization with an amplification ratio ≥2.0) 3. Newly diagnosed brain metastasis 4. At least one brain metastasis measuring ≥2.5cm (to minimise partial volume effects in PET imaging and quantification) 5. Previous treatment with Trastuzumab with or without Pertuzumab either in the adjuvant or metastatic setting 6. Discussed with neuro-oncology MDT and considered a candidate for macroscopic resection 7. ECOG performance status 0 to 2 8. Patient has adequate bone marrow and organ function as defined by the following laboratory values: 8.1. Absolute Neutrophil Count (ANC) > 1.0 x 109/L 8.2. Platelets (plt) >100 x 109/L 8.3. Haemoglobin (Hgb) ≥ 9 g/dl 8.4. INR ≤ 1.5 8.5. Potassium, calcium (corrected for serum albumin) and magnesium within normal limits 8.6. Serum creatinine ≤ 1.5 x ULN 8.7. Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) within normal range (or < 3.0 x ULN if liver metastases are present) 8.8. Total serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases are present; or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert’s Syndrome, which is defined as presence of several episodes of unconjugated hyperbilirubinemia with normal results from Cells Blood Count (CBC), including normal reticulocyte count and blood smear, normal liver function test results, and absence of other contributing disease processes at the time of diagnosis 8.9. Alkaline phosphatase ≤ 5 x upper limit of normal, unless bone metastases in the absence of liver disease 8.10. Fasting plasma glucose ≤ 120 mg/dL or 6.7 mmol/L 8.11. HbA1c ≤ 8 % (≤ 64mmol/mol) 9. Left ventricular Ejection Fraction (LVEF) > 50 % as determined echocardiogram 10. Life expectancy > 3 months 11. Ability to swallow and retain oral medication 12. Written informed consent, able to comply with treatment and follow up |
| Key exclusion criteria | 1. Prior treatment with Lapatinib or other HER2-directed tyrosine kinase inhibitor (given such patients will have already received some form of local therapy) 2. Cystic brain metastasis with minimal solid component (defined on MRI) 3. Prior treatment with either a P13K or AKT inhibitor 4. Receiving treatment with other antineoplastic agents (except for HER2-directed monoclonal antibody therapy) 5. Treated with any hematopoietic colony-stimulating growth factors (e.g., G-CSF, GM-CSF) ≤ 2 weeks prior to starting study drug. Erythropoietin or darbepoetin therapy, if initiated before enrollment, may be continued. 5. Wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia, bone marrow and organ functions) 6. Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects 7. Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or others), or patients with active severe personality disorders (defined according to DSM- IV). For patients with psychotropic treatments ongoing at baseline, the dose and the schedule should not be modified within the previous 6 weeks prior to start of study drug. For patients receiving psychotropic treatments at baseline, the dose and the schedule should not be modified within the previous 6 weeks prior to start of study drug. 8. GAD-7 mood scale ≥ 15 9. A score ≥ 12 on the PHQ-9 questionnaire 10. Selection of response “1, 2 or 3” to question number 9 on the PHQ-9 questionnaire regarding potential for suicidal thoughts or ideation (independent of the total score of the PHQ-9) 11. CTCAE grade 3 anxiety 12. Patient has active cardiac disease or a history of cardiac dysfunction including any of the following: 12.1. Unstable angina pectoris within 6 months prior to study entry 12.2. Symptomatic pericarditis 12.3. Documented myocardial infarction within 6 months prior to study entry 12.4. History of documented congestive heart failure (New York Heart Association functional classification III-IV) 12.5. Documented cardiomyopathy 13. QTcF > 480 msec on the screening ECG (using the QTcF formula) 14. Currently receiving treatment with medication that has a known risk to prolong the QT interval or inducing Torsades de Pointes, and the treatment cannot be discontinued or switched to a different medication prior to registration. 15. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of buparlisib 16. Prior malignancies (other than breast cancer) within the last 5 years, except for adequately treated in situ carcinoma of the cervix or basal cell/squamous cell carcinoma of the skin 17. Currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowed 18. Current treatment with drugs known to be moderate or strong inhibitors or inducers of isoenzyme CYP3A. Such agents must be discontinued for at least one week prior to starting treatment 19. History of non-compliance to medical regimen 20. Acute viral hepatitis or a history of chronic or active HBV or HCV infection, (typically defined by elevated AST/ALT (persistent or intermittent), high HBV DNA level, HBsAg positive, or high HCV RNA level (testing not mandatory) 21. Known history of HIV infection infection (testing not mandatory) 22. Other serious uncontrolled medical conditions or concurrent medical illness 23. Pregnant, lactating or potentially childbearing women not using adequate contraception 24. Adequate contraception is defined as either: 24.1. Total abstinence: When this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception. 24.2. Sterilization: have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment. 24.3. Male partner sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate). For female study subjects, the vasectomized male partner should be the sole partner for that patient. |
| Date of first enrolment | 10/04/2017 |
| Date of final enrolment | 10/04/2019 |
Locations
Countries of recruitment
- England
- Scotland
- United Kingdom
Study participating centres
The Royal Liverpool University Hospital
Prescot Street
Liverpool
L7 8XP
United Kingdom
Liverpool
L7 8XP
United Kingdom
The Walton Centre
Lower Lane
Fazakerley
Liverpool
L9 7LJ
United Kingdom
Fazakerley
Liverpool
L9 7LJ
United Kingdom
Clatterbridge Cancer Centre
Clatterbridge Road
Wirral
CH63 4JY
United Kingdom
Wirral
CH63 4JY
United Kingdom
Southampton General Hospital
Tremona Road
Southampton
SO16 6YD
United Kingdom
Southampton
SO16 6YD
United Kingdom
Queen Alexandra Hospital
Southwick Hill Road
Cosham
PO6 3LY
United Kingdom
Cosham
PO6 3LY
United Kingdom
The Beatson West of Scotland Cancer Centre
Department of Nuclear Medicine
1053 Great Western Road
Glasgow
G12 0YN
United Kingdom
1053 Great Western Road
Glasgow
G12 0YN
United Kingdom
The Queen Elizabeth University Hospital
1345 Govan Road
Govan
Glasgow
G51 4TF
United Kingdom
Govan
Glasgow
G51 4TF
United Kingdom
Salford Royal Hospital
Stott Lane
Salford
M6 8HD
United Kingdom
Salford
M6 8HD
United Kingdom
St Thomas’ Hospital
Westminster Bridge Road
Lambeth
London
SE1 7EH
United Kingdom
Lambeth
London
SE1 7EH
United Kingdom
Sponsor information
University of Liverpool
Hospital/treatment centre
Hospital/treatment centre
1-3 Brownlow Street
Liverpool
L69 3BX
England
United Kingdom
| Phone | +44 (0)151 794 8209 |
|---|---|
| hscott@liv.ac.uk | |
"ROR" |
https://ror.org/04xs57h96 |
Funders
Funder type
Charity
Cancer Research UK
Private sector organisation / Other non-profit organizations
Private sector organisation / Other non-profit organizations
- Alternative name(s)
- CR_UK, Cancer Research UK - London, CRUK
- Location
- United Kingdom
Novartis Pharmaceuticals UK Limited
Private sector organisation / For-profit companies (industry)
Private sector organisation / For-profit companies (industry)
- Alternative name(s)
- Novartis UK, NOVARTIS UK LIMITED
- Location
- United Kingdom
Results and Publications
| Intention to publish date | 10/10/2020 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | The main trial results will be published in the name of the trial in a peer-reviewed journal, on behalf of all collaborators. |
| IPD sharing plan | The current data sharing plans for the current study are unknown and will be made available at a later date. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| HRA research summary | 28/06/2023 | No | No |
Editorial Notes
13/07/2018: The trial was closed during the set-up phase as the drug developer involved in the trial made the decision to halt development of the study IMP.
